S100A6 and breast carcinoma: The first, an analysis of 202 PR-positive breast cancers by immunoblotting, showed that while there was no significant difference in levels of PRA and PRB in most of the PR-positive tumors, nevertheless expression levels of PRA were higher in 59% of tumors and at least four times as high in 25% [29].